Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Galera Therapeutics Inc (NQ: GRTX ) 0.1450 UNCHANGED Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Galera Therapeutics Inc Galera Announces Board Approval of Complete Liquidation and Dissolution August 14, 2024 Company reports second quarter 2024 financial results From Galera Therapeutics Via GlobeNewswire Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates May 13, 2024 Company’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value From Galera Therapeutics Via GlobeNewswire Galera Adopts Limited Duration Stockholder Rights Agreement May 03, 2024 From Galera Therapeutics Via GlobeNewswire Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates March 28, 2024 Company continues to evaluate strategic options to maximize shareholder value From Galera Therapeutics Via GlobeNewswire Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates November 14, 2023 From Galera Therapeutics Via GlobeNewswire Galera Announces Receipt of Type A Meeting Minutes and Strategic Update October 31, 2023 From Galera Therapeutics Via GlobeNewswire Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem September 18, 2023 From Galera Therapeutics Via GlobeNewswire Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From Galera Therapeutics Via GlobeNewswire Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates August 14, 2023 From Galera Therapeutics Via GlobeNewswire Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese August 09, 2023 From Galera Therapeutics Via GlobeNewswire Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting June 05, 2023 From Galera Therapeutics Via GlobeNewswire Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer May 18, 2023 Rucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy From Galera Therapeutics Via GlobeNewswire Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates May 11, 2023 From Galera Therapeutics Via GlobeNewswire Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 04, 2023 From Galera Therapeutics Via GlobeNewswire Galera Expands Commercial Leadership Team May 01, 2023 From Galera Therapeutics Via GlobeNewswire Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Galera Therapeutics Via GlobeNewswire Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology March 10, 2023 From Galera Therapeutics Via GlobeNewswire Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates March 08, 2023 From Galera Therapeutics Via GlobeNewswire Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants February 15, 2023 From Galera Therapeutics Via GlobeNewswire Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis February 15, 2023 From Galera Therapeutics Via GlobeNewswire Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis December 12, 2022 NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patients From Galera Therapeutics Via GlobeNewswire Galera to Present at Piper Sandler Annual Healthcare Conference November 22, 2022 From Galera Therapeutics Via GlobeNewswire Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates November 09, 2022 From Galera Therapeutics Via GlobeNewswire Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting October 26, 2022 From Galera Therapeutics Via GlobeNewswire The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026 December 21, 2021 Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... Via FinancialNewsMedia Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics December 15, 2021 Palm Beach, FL – December 15, 2021 – FinancialNewsMedia.com News Commentary – Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also... Via FinancialNewsMedia Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.